* Viracta Therapeutics Inc is expected to show no change in quarterly revenue when it reports results on August 12 (estimated) for the period ending June 30 2024
*
* LSEG's mean analyst estimate for Viracta Therapeutics Inc is for a loss of 37 cents per share.
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the last three months.
* Wall Street's median 12-month price target for Viracta Therapeutics Inc is $5.00, above its last closing price of $0.44.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Mar. 31 2024 -0.35 -0.35 -0.23 Beat 34.8
Dec. 31 2024 -0.34 -0.31 -0.35 Missed -12.9
Sep. 30 2023 -0.30 -0.30 -0.33 Missed -8.2
Jun. 30 2023 -0.30 -0.29 -0.32 Missed -10.3
Jan. -0.31 -0.31 -0.32 Missed -2.4
1 0001
Dec. 31 2022 -0.33 -0.38 -0.27 Beat 29.9
Sep. 30 2022 -0.30 -0.30 -0.47 Missed -54.1
Jun. 30 2022 -0.30 -0.30 -0.28 Beat 5.9
This summary was machine generated August 9 at 16:55 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments